Title: 

A compound for use in the prevention and/or treatment of endoplasmic reticulum stress-dependent neurodegenerative diseases. 

Status ochrony: 

Patent – EP3815682A1; Patent No Pat.241218 

Subject: 

The subject of the invention is a compound of general formula I, for use as a drug, an inhibitor of PERK kinase in the eIF2α factor-dependent pathway, as well as its use in the prevention and treatment of neurodegenerative diseases dependent on endoplasmic reticulum stress, as well as cancer diseases. 

Benefits: 

Early diagnosis of neurodegenerative diseases at the molecular level – prevention in the early stages of disease development. The inhibitor shows high activity at the cellular level while lacking cytotoxicity towards human cells – the safety of the drug and the possibility of its application as a more effective compound that reduces side effects occurring in chemotherapy treatment of cancer. 

Stage of work: 

The studies at the preclinical research stage. 

Application: 

Specific PERK kinase inhibitors may be potentially used as an active substance in the process of new drugs formulation. A compound usable in the prevention and/or treatment of neurodegenerative diseases dependent on endoplasmic reticulum stress – glaucoma, Alzheimer’s disease, Parkinson’s disease, as well as in the treatment of cancer diseases. 

Contact: 

@:  sylwia.grzelak@umed.lodz.pl, tel.: 502 447 575